US 12,367,692 B2
Systems for automated in situ hybridization analysis
Srinivas Chukka, Tucson, AZ (US); Thomas M. Grogan, Tucson, AZ (US); and Anindya Sarkar, Tucson, AZ (US)
Assigned to Ventana Medical Systems, Inc., Tucson, AZ (US)
Filed by Ventana Medical Systems, Inc., Tucson, AZ (US)
Filed on May 17, 2024, as Appl. No. 18/668,118.
Application 18/668,118 is a continuation of application No. 17/263,452, granted, now 12,020,493, previously published as PCT/US2019/041257, filed on Jul. 10, 2019.
Claims priority of provisional application 62/711,049, filed on Jul. 27, 2018.
Prior Publication US 2024/0304006 A1, Sep. 12, 2024
Int. Cl. G06K 9/00 (2022.01); G06V 20/69 (2022.01)
CPC G06V 20/69 (2022.01) 18 Claims
OG exemplary drawing
 
1. A method comprising:
acquiring a first image depicting a portion of a biological sample stained for a presence of one or more first biomarkers and a second image depicting a portion of the biological sample stained for a presence of one or more second biomarkers;
identifying cells in the first image having staining intensity levels that satisfy predetermined expression levels;
identifying tissue regions in the first image encompassing the cells identified in the first image;
identifying mapped tissue regions in the second image by mapping the tissue regions identified in the first image to the second image;
detecting signals in the mapped tissue regions that correspond to at least one second biomarker of the one or more second biomarkers; and
assessing whether nuclei in the mapped tissue regions have genetic aberrations based on the signals, wherein a portion of the signals correspond to a first nucleic acid biomarker and a portion of the signals correspond to a second nucleic acid biomarker, and wherein assessing whether nuclei in the mapped tissue regions have genetic aberrations based on the signals comprises calculating a ratio of dots corresponding to the portion of the signals corresponding to the first nucleic acid biomarker to dots corresponding to the portion of the signals corresponding to the second nucleic acid biomarker.